Literature DB >> 15111319

Prevalent overexpression of prolyl isomerase Pin1 in human cancers.

Lere Bao1, Amy Kimzey, Guido Sauter, Janusz M Sowadski, Kun Ping Lu, Da-Gong Wang.   

Abstract

Phosphorylation of proteins on serine or threonine residues preceding proline (pSer/Thr-Pro) is a major regulatory mechanism in cell proliferation and transformation. Interestingly, the pSer/Thr-Pro motifs in proteins exist in two distinct cis and trans conformations, whose conversion rate is normally reduced on phosphorylation, but is catalyzed specifically by the prolyl isomerase Pin1. Pin1 can catalytically induce conformational changes in proteins after phosphorylation, thereby having profound effects on catalytic activity, dephosphorylation, protein-protein interactions, subcellular location, and/or turnover of certain phosphorylated proteins. Recently, it has been shown that Pin1 is overexpressed in human breast cancer cell lines and cancer tissues and plays a critical role in the transformation of mammary epithelial cells by activating multiple oncogenic pathways. Furthermore, Pin1 expression is an excellent independent prognostic marker in prostate cancer. However, little is known about Pin1 expression in other human normal and cancerous tissues. In the present study, we quantified Pin1 expression in 2041 human tumor samples and 609 normal tissue samples as well as normal and transformed human cell lines. We found that Pin1 was usually expressed at very low levels in most normal tissues and its expression was normally associated with cell proliferation, with high Pin1 levels being found only in a few cell types. However, Pin1 was strikingly overexpressed in many different human cancers. Most tumors (38 of 60 tumor types) have Pin1 overexpression in more than 10% of the cases, as compared with the corresponding normal controls, which included prostate, lung, ovary, cervical, brain tumors, and melanoma. Consistent with these findings, Pin1 expression in human cancer cell lines was also higher than that in the normal cell lines examined. These results indicate that Pin1 overexpression is a prevalent and specific event in human cancers. Given previous findings that Pin1 expression is an excellent prognostic marker in prostate cancer and that inhibition of Pin1 can suppress transformed phenotypes and inhibit tumor cell growth, these findings may have important implications for the pathogenesis, diagnosis, and treatment of human cancers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15111319      PMCID: PMC1615639          DOI: 10.1016/S0002-9440(10)63731-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Phosphorylation-dependent proline isomerization catalyzed by Pin1 is essential for tumor cell survival and entry into mitosis.

Authors:  J F Rippmann; S Hobbie; C Daiber; B Guilliard; M Bauer; J Birk; H Nar; P Garin-Chesa; W J Rettig; A Schnapp
Journal:  Cell Growth Differ       Date:  2000-07

2.  Pin1 acts catalytically to promote a conformational change in Cdc25.

Authors:  P T Stukenberg; M W Kirschner
Journal:  Mol Cell       Date:  2001-05       Impact factor: 17.970

3.  Drosophila Pin1 prolyl isomerase Dodo is a MAP kinase signal responder during oogenesis.

Authors:  T Hsu; D McRackan; T S Vincent; H Gert de Couet
Journal:  Nat Cell Biol       Date:  2001-06       Impact factor: 28.824

Review 4.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

5.  Tissue microarrays (TMAs) for high-throughput molecular pathology research.

Authors:  A Nocito; J Kononen; O P Kallioniemi; G Sauter
Journal:  Int J Cancer       Date:  2001-10-01       Impact factor: 7.396

6.  Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.

Authors:  G M Wulf; A Ryo; G G Wulf; S W Lee; T Niu; V Petkova; K P Lu
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

7.  The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.

Authors:  P J Lu; G Wulf; X Z Zhou; P Davies; K P Lu
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

8.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

Authors:  J Torhorst; C Bucher; J Kononen; P Haas; M Zuber; O R Köchli; F Mross; H Dieterich; H Moch; M Mihatsch; O P Kallioniemi; G Sauter
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

Review 9.  The Rb/E2F pathway and cancer.

Authors:  J R Nevins
Journal:  Hum Mol Genet       Date:  2001-04       Impact factor: 6.150

10.  Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC.

Authors:  A Ryo; M Nakamura; G Wulf; Y C Liou; K P Lu
Journal:  Nat Cell Biol       Date:  2001-09       Impact factor: 28.824

View more
  143 in total

1.  An NF-κB p65-cIAP2 link is necessary for mediating resistance to TNF-α induced cell death in gliomas.

Authors:  Xueyan Zhao; Travis Laver; Suk W Hong; George B Twitty; Annelies Devos; Marijke Devos; Etty N Benveniste; Susan E Nozell
Journal:  J Neurooncol       Date:  2011-01-30       Impact factor: 4.130

2.  Peptidyl-prolyl isomerase Pin1 controls down-regulation of conventional protein kinase C isozymes.

Authors:  Hilde Abrahamsen; Audrey K O'Neill; Natarajan Kannan; Nicole Kruse; Susan S Taylor; Patricia A Jennings; Alexandra C Newton
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

3.  Mitotic regulation of SEPT9 protein by cyclin-dependent kinase 1 (Cdk1) and Pin1 protein is important for the completion of cytokinesis.

Authors:  Mathew P Estey; Caterina Di Ciano-Oliveira; Carol D Froese; Karen Y Y Fung; Jonathan D Steels; David W Litchfield; William S Trimble
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

4.  Peptidyl-prolyl cis/trans isomerase-independent functional NifH mutant of Azotobacter vinelandii.

Authors:  Nara Gavini; Sudheer Tungtur; Lakshmi Pulakat
Journal:  J Bacteriol       Date:  2006-08       Impact factor: 3.490

5.  Expression of Pin1 and Ki67 in cervical cancer and their significance.

Authors:  Hongyu Li; Hongling Shen; Qian Xu; Dongrui Deng; Shixuan Wang; Yunping Lu; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

6.  Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.

Authors:  Min Zheng; Huijuan Xu; Xin-Hua Liao; Champ Peng Chen; Arina Li Zhang; Wenxian Lu; Long Wang; Dayun Yang; Jichuang Wang; Hekun Liu; Xiao Zhen Zhou; Kun Ping Lu
Journal:  Oncotarget       Date:  2017-05-02

7.  Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase gene.

Authors:  Kyle A Edgar; Marcia Belvin; Annette L Parks; Kellie Whittaker; Matt B Mahoney; Monique Nicoll; Christopher C Park; Christopher G Winter; Feng Chen; Kim Lickteig; Ferhad Ahmad; Hanife Esengil; Matthew V Lorenzi; Amanda Norton; Brent A Rupnow; Laleh Shayesteh; Mariano Tabios; Lynn M Young; Pamela M Carroll; Casey Kopczynski; Gregory D Plowman; Lori S Friedman; Helen L Francis-Lang
Journal:  Genetics       Date:  2005-03-02       Impact factor: 4.562

8.  Pin1 interacts with the Epstein-Barr virus DNA polymerase catalytic subunit and regulates viral DNA replication.

Authors:  Yohei Narita; Takayuki Murata; Akihide Ryo; Daisuke Kawashima; Atsuko Sugimoto; Teru Kanda; Hiroshi Kimura; Tatsuya Tsurumi
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

9.  Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis.

Authors:  Gerburg Wulf; Priti Garg; Yih-Cherng Liou; Dirk Iglehart; Kun Ping Lu
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

10.  The prolyl isomerase Pin1 is overexpressed in human esophageal cancer.

Authors:  Huawei Jin; Jie Jiang; Lifang Sun; Fangfang Zheng; Chengyan Wu; Lin Peng; Yufen Zhao; Xueji Wu
Journal:  Oncol Lett       Date:  2011-08-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.